Evidence of Infection with Simian Type D Retrovirus in Persons Occupationally Exposed to Nonhuman Primates

Transcription

1 JOURNAL OF VIROLOGY, Feb. 2001, p Vol. 75, No X/01/$ DOI: /JVI Copyright 2001, American Society for Microbiology. All Rights Reserved. Evidence of Infection with Simian Type D Retrovirus in Persons Occupationally Exposed to Nonhuman Primates NICHOLAS W. LERCHE, 1 * WILLIAM M. SWITZER, 2 JOANN L. YEE, 1 VEDAPURI SHANMUGAM, 2 ANN N. ROSENTHAL, 1 LOUISA E. CHAPMAN, 2 THOMAS M. FOLKS, 2 AND WALID HENEINE 2 Simian Retrovirus Laboratory, California Regional Primate Research Center, University of California, Davis, Davis, California , 1 and HIV and Retrovirology Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia Received 7 August 2000/Accepted 20 November 2000 Simian type D retrovirus (SRV) is enzootic in many populations of Asian monkeys of the genus Macaca and is associated with immunodeficiency diseases. However, the zoonotic potential of this agent has not been well defined. Screening for antibodies to SRV was performed as part of an ongoing study looking for evidence of infection with simian retroviruses among persons occupationally exposed to nonhuman primates (NHPs). Of 231 persons tested, 2 (0.9%) were found to be strongly seropositive, showing reactivity against multiple SRV antigens representing gag, pol, and env gene products by Western immunoblotting. Persistent long-standing seropositivity, as well as neutralizing antibody specific to SRV type 2, was documented in one individual (subject 1), while waning antibody with eventual seroreversion was observed in a second (subject 2). Repeated attempts to detect SRV by isolation in tissue culture and by using sensitive PCR assays for amplification of two SRV gene regions (gag and pol) were negative. Both individuals remain apparently healthy. We were also unable to transmit this seropositivity to an SRV-negative macaque by using inoculation of whole blood from subject 1. The results of this study provide evidence that occupational exposure to NHPs may increase the risk of infection with SRV and underscore the importance of both occupational safety practices and efforts to eliminate this virus from established macaque colonies. * Corresponding author. Mailing address: California Regional Primate Research Center, University of California, Davis, One Shields Ave., Davis, CA Phone: (530) Fax: (530) nwlerche@ucdavis.edu. Nonhuman primates (NHPs) are the natural hosts of a number of exogenous retroviruses, including simian immunodeficiency virus (SIV), simian T-cell lymphotropic virus (STLV), simian foamy virus (SFV), and simian type D retrovirus (SRV) (21). The close phylogenetic relationship between humans and NHPs increases the potential for cross-species transmission of these retroviral agents (33). Retroviral zoonoses have received increased attention both because of the growing body of evidence indicating that human immunodeficiency viruses types 1 and 2 originated from cross-species transmission of closely related viruses of chimpanzees (Pan troglodytes troglodytes) and sooty mangabeys (Cercocebus atys), respectively (6), and because of recent serious consideration given to the use of NHPs as potential organ donors for human xenotransplantation (1). Although the risk factors associated with cross-species transmission remain poorly defined, human infections with both SIV and SFV have recently been identified in individuals occupationally exposed to NHPs or their tissues (10, 12). Occupational exposure to simian retroviruses is of concern not only with regard to the potential adverse health effects for individual workers who are occasionally infected but also because of the potential for introduction of animal retroviruses into the general human population through secondary transmission from infected workers to intimate contacts. The exogenous simian type D retroviruses are a group of closely related viruses that are enzootic in many captive and wild populations of macaques (genus Macaca) (18). In macaques, SRV has been identified as the etiologic agent of an infectious immunodeficiency disease that bears some clinical resemblance to AIDS in humans (18). In infected macaques, SRV may be present in blood, saliva, urine, and other body fluids, and a significant risk of exposure can reasonably be assumed in persons employed in the care and handling of NHPs (18). This is particularly true for workers employed before the current widespread use of personal protective equipment. Furthermore, the risk of exposure to NHPs and their body fluids was recently highlighted in a study that found a high frequency of needle sticks and mucocutaneous exposures in persons who reported working primarily with macaques, the NHPs most frequently used in biomedical research (30). Although SRV is known to replicate in cells of human origin (17), the zoonotic potential of this virus has not been thoroughly investigated. Since the early 1970s, a number of surveys have been conducted to search for evidence of human infection with SRV. Most of these, however, were carried out in groups of patients with specific diagnoses (8, 19, 25) or in populations with no specific exposure to NHPs (4, 26, 27). For the majority of these studies, the results have been inconclusive, describing only partial seroreactivity, most commonly to a single SRV gag gene product (e.g., p25 or p27) by Western immunoblotting (WB) (4, 8, 19, 25 27). Type D retroviruses have also been isolated from human cell lines in culture, but the majority of these infections have been attributed to laboratory contamination (13, 28). In one study, detection of Mason-Pfizer monkey virusrelated env-pol sequences by PCR in children with Burkitt s lymphoma was reported (14), but other studies have found no evidence of type D retrovirus infection in patients with non- Hodgkin s lymphoma or other lymphoproliferative or immunosuppressive illnesses (8). 1783

2 1784 LERCHE ET AL. J. VIROL. The most compelling evidence to date of human SRV infection involved a homosexual male AIDS patient with lymphoma (2). SRV was isolated from the patient s lymphoma tissue, his bone marrow was positive for integrated proviral DNA for two viral regions by PCR, and antibodies to both gag and env SRV viral gene products were detected in the patient s serum by WB and radioimmunoprecipitation. (2). Characterization of this isolate revealed a close relationship to Mason-Pfizer monkey virus, the prototype simian type D retrovirus (now called SRV serotype 3 [SRV-3]), and to SRV-1 (5). This individual had no known history of contact with NHPs or their blood or tissues, and the source of his infection remains unknown. An ongoing survey of individuals occupationally exposed to NHPs has recently identified human infections with two other exogenous simian retroviruses, SIV and SFV (10). Here we report the findings of SRV surveillance among the same cohort. MATERIALS AND METHODS Human subjects. As part of ongoing voluntary prospective surveillance for human infections with simian retroviruses among workers occupationally exposed to NHPs or their tissues, body fluids, or viruses, serum samples from 231 workers from 13 institutions in North America were tested for antibodies against SRV. Informed consent was obtained from all participants, and each participant completed a questionnaire regarding employment and potential exposure history. Additional archived as well as follow-up blood specimens were requested and obtained for analysis from individuals found to be positive or indeterminate on initial antibody testing. Screening for antibodies to SRV. Serum specimens were obtained from coagulated blood and stored at 20 or 70 C until use. A four-tiered testing algorithm was used. Serum specimens were screened for the presence of antibodies to SRV by enzyme immunoassay (EIA) using SRV-1 and SRV-2 viral antigens as previously described (19). An optical density (OD) value that was twice the mean value of standard negative control sera run on the same plate was used as the cutoff. All specimens with OD values less than the cutoff were considered negative. All other specimens were further tested by WB. In addition, to increase the sensitivity of the EIA, sera with OD values below but within 20% of the calculated cutoff value were also further tested by WB. WB testing was performed using a 1:100 serum dilution against double-banded sucrose gradient-purified SRV-1 and SRV-2 as described previously (19). Criteria for WB positivity included reactivity to at least one gag-coded antigen (p24 or p27) and to at least one env gene product (gp20 or gp70). Sera showing no reactivity to these antigens were considered negative. Sera showing reactivity to a single viral protein were considered indeterminate. All nonnegative (i.e., positive and indeterminate) sera were further tested using an indirect immunofluorescence assay (IFA). IFA testing was done using a 1:10 dilution of serum reacted against SRV-1- and/or SRV-2-infected SupT1 cells and uninfected SupT1 cells. Fluorescein isothiocyanate-labeled goat anti-human immunoglobulin G was used to detect the reaction. Criteria for a positive IFA result included reactivity to infected (but not uninfected) cells. Sera that did not react to infected cells were considered negative and were not further tested. If nonspecific reactivity to both infected and uninfected cells was detected, the test was considered uninterpretable. All remaining sera which could not be interpreted as negative after the first three levels of testing were retested by WB using absorbed and unabsorbed aliquots of serum. An aliquot of serum, diluted and absorbed overnight at 4 C against 10 7 uninfected cells (the same cell lines used for propagation of SRV for antigen production), was tested in parallel with an unabsorbed aliquot by WB. Absorbed sera continuing to demonstrate reactivity to major gag (p24 or p27) and env (gp20 or gp70) gene products were considered positive. Absorbed sera showing no reactivity to these proteins were considered negative. Sera continuing to demonstrate reactivity to a single viral gene product were considered seroindeterminate. All serologic testing was performed in a blinded fashion. Samples from SRV-1- and SRV-2-seropositive and -seronegative monkeys were included as controls for all tests. Neutralization assay. Serum was tested for neutralizing activity against both SRV-1 and SRV-2 as previously described (22), with modifications. Briefly, serial twofold dilutions (1:10 to 1:640; final volume, 0.5 ml per well) of heat-inactivated (56 C for 30 min) sera with assay medium (RPMI 1640, 10% heat-inactivated fetal calf serum, L-glutamine, and Fungibact) were incubated for 30 min at 37 C with 0.5 ml of medium containing 40 50% tissue culture infective doses (TCID 50 ) of SRV-1 or 80 TCID 50 of SRV-2 in 24-well microtiter plates. Cultures were held at 37 C and 5% CO 2 with daily observations for cytopathic effect (CPE). Cells were harvested on day 5, and slides were prepared for IFA as previously described (17). SRV-1- and SRV-2-positive control sera were from a naturally infected rhesus macaque and cynomolgus macaque, respectively. WB-negative macaque and human sera were used as negative controls. Both CPE observations and IFA results were recorded for each well. The reported titer is the highest dilution that completely inhibited CPE and gave a negative IFA result. Virus isolation. Peripheral blood lymphocytes (PBLs) were obtained from EDTA-treated whole blood by Ficoll-Hypaque separation. Following stimulation with phytohemagglutinin A or interleukin 2 for 48 h, to PBLs were cocultivated with equivalent amounts of either 2-day PHA-stimulated normal donor PBLs or the SRV permissive Raji B cell line using standard tissue culture techniques. The Raji cocultures were maintained in assay medium, and the PBL-PBL cocultures were maintained in assay medium with 10% interleukin 2. The PBL cocultures were fed with fresh 2-day PHA-stimulated PBLs every 10 days. All cocultures were maintained for 40 to 50 days and were monitored biweekly for CPE, for reverse transcriptase (RT) activity by using the Amp-RT assay (9), and for proviral SRV gag sequences by PCR as described below. PCR analysis. PBL lysates were prepared from whole, unfractionated EDTAtreated blood specimens as previously described (31). In addition, monocyte, B-cell, CD4 T-cell, and CD8 T-cell subsets were enriched for by positive selection of the PBLs by using immunomagnetic beads directly conjugated with antibodies to CD19 (B cell), CD14 (monocytes and macrophages), CD4 (T lymphocytes and monocytes), and CD8 (T-cytotoxic and suppressor cells) (Dynal), as described elsewhere (3). All whole-cell and subset populations were lysed for PCR analysis at a concentration of cells per ml. In addition, DNA lysates were made from leukocyte nuclei obtained by sucrose lysis of 1 ml of whole blood, as previously described (7). Detection of human beta-globin sequences in the whole and enriched PBL fractions and the nuclear lysates was done to ensure the presence of amplifiable DNA in each sample. Degenerate SRV primers for nested PCR were designed based on alignments of the gag and pol genes of SRV-1, SRV-2, and SRV-3 (GenBank accession numbers M11841, M16605, and M12349, respectively). Wobble bases and inosines were used to accommodate nucleotide variability at certain positions in these oligonucleotides. All primer and probe sequences are described in Table 1. Titration analysis indicated that each nested PCR assay had a detection sensitivity equivalent to DNA from 1.5 to 0.15 SRV-infected cells in a background of DNA from 150,000 uninfected human PBLs (Fig. 1A). These primers could also detect SRV-4 and -5 with equivalent levels of sensitivity (Fig. 1A). In addition, we have also developed SRV-2-specific PCR primers and probes, since both seropositive persons demonstrated SRV-2-specific neutralizing-antibody reactivity (described in Results) (Table 1). This SRV-2-specific PCR assay had a detection threshold of DNA equivalent to 1.5 SRV-2-infected cells in a background of DNA from 150,000 uninfected PBLs (data not shown). PBL lysates equivalent to 1 to 1.5 g of DNA were used in all PCR assays in 100- l reaction volumes containing 100 ng of each sense and antisense primer, 2.5 U of Taq polymerase, a 1.25 mm concentration of each deoxynucleoside triphosphate, 10 mm Tris-HCl (ph 8.3), 50 mm KCl, and 1.5 mm MgCl 2. Forty cycles of amplification were performed at 94 C for 1 min, 45 C for 1 min, and 72 C for 1 min. Five microliters of the first-round amplification product was used in a nested PCR assay using the nested primers listed in Table 1 and the primary amplification conditions. Twenty microliters of the PCR products were electrophoresed on a 1.8% agarose gel that was Southern blot hybridized with the respective 32 P-, end-labeled internal gag or pol oligoprobes. Animal inoculation. A single juvenile rhesus macaque, negative for SIV, STLV, SFV, and SRV, was inoculated intravenously with 10 ml of heparinized whole blood obtained from an animal handler with persistent SRV seropositivity (subject 1). The experimental use and housing of this macaque was in accordance with guidelines set by the laboratory animal care and use committees at the respective institutions. Follow-up blood samples were obtained weekly for 2 weeks, then biweekly for 8 weeks, then monthly for 9 months. Also, an axillary lymph node biopsy was obtained at 5 months postinoculation. Serum samples were tested for SRV-specific antibody by WB. At each sampling time point, virus isolation was attempted by cocultivation of PBLs with both Raji and SupT1 cells, as previously described (17). Cultures were monitored for the appearance of CPE, and supernatant and cells were collected for RT assay and SRV PCR, respectively, on day 7 and weekly thereafter for 6 weeks. For PCR, 10 7 cells were lysed in PCR cell lysis buffer and tested as described elsewhere (20). A single suspension of lymph node cells was prepared from the axillary lymph node biopsy and processed for culture and PCR as described above.

3 VOL. 75, 2001 HUMAN SRV INFECTION 1785 TABLE 1. Nested PCR primer pairs used for detection of SRV sequences in blood specimens and tissue culture samples from SRV-seropositive persons Primer or probe Nucleotide sequence a Fragment size (bp) Gene region Outer pair p27f1 5 -GAATCTGTAGCGGA(C/T)AATTGGCTT gag p27r1 5 -GGGCG(A/G)AT(G/T)GCTGC(C/T)TGACA-3 Inner pair p27f2 5 -ACTTGTTAGGGCAGTCCT(C/T)TC(A/T)GG gag p27r2 5 -ACAGGCTGG(A/G)TTAGC(A/G)TTTTCATA-3 Probe p27p3 5 -GTCAAACAAGGACCIGATGAICC-3 gag Outer pair b 2p27F1 5 -GAATCCATCGCCGATAATTGGCTT gag 2p27R1 5 -ATTGCTGCTTGACAGGCTGGGTTA-3 Inner pair 2p27F2 5 -GAAAATCAACAGGCAAGGGAATGGCT gag 2p27R2 5 -TGCGAATGGTTCATCAGGTCCTTG-3 Probe 2p27P1 5 -CGCCACGAACGCCTGGAGAAAACCT-3 gag Outer pair SRVPOLF1 5 -TACCAITICCTCATTTIGGAGTTAATCC pol SRVPOLR1 5 -AAAGAGTGCITGATTGAGIATITTCCTG-3 Inner pair SRVPOLF2 5 -(G/A)ITICCCAAIAATGITITGGCAAATGGA pol SRVPOLR2 5 -AGGIIGICCAAATAATAGAGAAGCAATG-3 Probe SRVPOLP3 5 -TCIATAGATACITTIAGTGGATTCCT-3 pol a Primer pairs were designed according to an alignment of SRV-1, -2, and -3 sequences (GenBank accession numbers M11841, M16605, and M12349, respectively). Wobble bases (N/N) and inosines (I) were used to accommodate nucleotide variability at certain positions in these oligonucleotides. b Primer pair specific for SRV-2. DNA extracted from inoculated monkey PBLs were analyzed by PCR and nested PCR for the presence of SRV proviral DNA using SRV primers capable of simultaneous detection of SRV-1, -2, and -3 as previously described (20). RESULTS Screening for antibodies to SRV. Of 231 sera tested for SRV antibodies by EIA, 60 were found to be reactive or near the cutoff and were further tested by WB. Of these, 46 were determined to be negative and 12 were seroindeterminate, showing reactivity to a single gene product (p27). In further testing of these 12 samples by IFA, 5 were negative and 7 showed nonspecific reactivity (equal staining intensity and pattern in SRV-infected and -uninfected cells). Two of these 60 sera, however (cases 1 and 2), were found to have antibodies reactive against gag, pol, and env gene products of both SRV-1 and SRV-2 by WB on initial testing (Fig. 2). Both sera showed reactivity against p16, gp20, p24, p27, and p31 for both SRV-1 and SRV-2 (Fig. 2). Both blot-positive sera were also positive by IFA. Subsequent WB testing of two archived samples collected in 1995 from subject 1 found both to be SRV-1 positive (Fig. 3) and SRV-2 positive (data not shown), showing persistent seropositivity of at least 3 years duration for this person. In contrast, two archived sera from subject 2 collected in 1994 were both negative for SRV antibodies (Fig. 3). In addition, the follow-up serum sample collected from subject 2 in 1997 was weakly positive against both SRV-1 (Fig. 3) and SRV-2 (data not shown), and the sample collected in 1998 was negative for SRV antibodies, indicating waning SRV antibody and eventual seroreversion after the initial positive sample, which had been collected in 1996 (Fig. 3). The apparent loss of reactivity to the putative pol gene product (p31) and the lesser gag proteins (p14 and p16), present in WB of initial samples (Fig. 2), in WB of archival and follow-up sera (Fig. 3) reflects the variable presence of these antigens, which is commonly seen in different lots of antigen. Patient histories. In the questionnaire and a personal interview, subject 1 described handling a variety of NHPs, including African green monkeys (AGM), pig-tailed macaques, and squirrel monkeys, for 23 years. During that time, subject 1 reported multiple exposures to NHP blood, body fluids, and fresh tissue, including two bite wounds by an AGM prior to 1975 that required suturing and a cut during necropsy of a squirrel monkey. Subject 1 had been shown previously to be infected with SFV originating from an AGM (10). Subject 2 reported working with NHPs such as rhesus and cynomolgus macaques, baboons, and owl monkeys for about 5 years and described receiving scratch wounds from a rhesus and a cynomolgus macaque in 1994 and 1996, respectively. In addition, subject 2 reported receiving scratch wounds from cages and pans used to house these macaques. Both subjects reported performing invasive procedures with NHPs, including venipuncture, tooth extraction, and surgery. Both subject 1 and subject 2 have remained in apparent good health. Spouses of the subjects were not available for testing to determine the transmissibility of the observed seroreactivity. Neutralizing activity. Neutralization assays were performed with sera collected from both persons, using samples with evidence of stronger SRV seropositivity in each case, to determine if the observed seroreactivity was due to a specific SRV serotype. Serum collected from subject 1 was found to have a

4 1786 LERCHE ET AL. J. VIROL. FIG. 1. (A) Sensitivity analysis of generic SRV gag PCR assay. The first 15 lanes contain reaction mixtures containing DNA lysates from 150,000 uninfected human PBLs spiked with DNA lysates equivalent to 15, 1.5, and 0.15 SupT1 cells infected with each respective SRV serotype; controls include DNA lysate from uninfected human PBLs (NEG) and water-only negative controls for the primary and nested PCR amplifications. (B to D) Proviral PCR analysis of SRV gag and pol sequences in DNA lysates prepared from unfractionated, fractionated, and nuclear PBLs from seropositive animal handlers. (B) Generic gag PCR; (C) generic pol PCR; (D) SRV-2-specific gag PCR. PBL-96 and PBL-97, DNA lysates prepared from unfractionated PBLs collected in 1996 and 1997, respectively, from subjects 1 and 2; NUC-96 and NUC-97, DNA lysates prepared from leukocyte nuclei collected at the same time points as the unfractionated PBLs; CD14, CD19, CD8, and CD4, DNA lysates prepared from monocyte-, B lymphocyte-, T-suppressor lymphocyte-, and T-helper lymphocyte-enriched PBL fractions, respectively; NEG, DNA lysate from uninfected human PBLs; H 2 O, water-only negative controls for the primary and nested PCR amplifications. The last two lanes show sensitivity controls containing DNA lysates from 150,000 uninfected human PBLs spiked with DNA lysates equivalent to 15 and 0.15 SupT1 cells infected with SRV-2. Not shown are the negative results for the unfractionated PBL samples collected from both subjects in moderately high titer of neutralizing antibody (1:160) against SRV-2 (Table 2). Similarly, subject 2 had detectable neutralizing antibody (1:40) against SRV-2 but at lower levels than that seen in subject 1 (Table 2). These data suggest that both subjects may have been exposed to SRV-2. Virus isolation. Attempts to isolate SRV from PBL of both seropositive persons, including at two time points for subject 1, by coculture with either normal donor PBLs or Raji cells were negative. During the 40 to 50 days in culture, there was no evidence of any markers of retroviral infection, such as CPE or RT activity. In addition, PCR analysis of tissue culture cells collected biweekly was negative for SRV gag sequences, suggesting the absence of latent, nonproductive infection of either the donor PBLs or Raji cells. PCR analysis. Abundant -globin sequences were readily amplified from all unfractionated and fractionated PBL and nuclear PCR lysates, indicating the absence of PCR inhibitors and adequate DNA integrity in the test material (data not shown). All attempts to detect SRV proviral DNA from both PBL lysates from both subjects using generic SRV primers for both gag and pol sequences were negative. These negative PCR FIG. 2. WB reactivity against SRV-1 and SRV-2 on initial screening in sera from two persons occupationally exposed to NHPs. Lanes:, SRV-positive control;, SRV-negative control; 1, subject 1 (sample date, 23 September 1996); 2, subject 2 (sample date, 20 November 1996). MW, molecular weight (weights are in thousands).

5 VOL. 75, 2001 HUMAN SRV INFECTION 1787 FIG. 3. WB results for SRV-1 on archival and follow-up serum samples from two persons identified as SRV seropositive on initial screening. Lanes:, positive monkey control;, negative monkey control (left) and negative human control (right); 1 to 7, subject 1 samples from 1 May 1995, 11 June 1995, 23 September 1996, 24 September 1996, 13 January 1997, 27 January 1997, and 31 July 1998, respectively; 8 to 12, subject 2 samples from 26 April 1994, 24 October 1994, 20 November 1996, 30 January 1997, and 18 December 1998, respectively. MW, molecular weight (weights are in thousands). results were seen in four PBL samples from subject 1 and in two PBL samples from subject 2, both collected longitudinally over a period of 2 to 3 years (Fig. 1B and C). However, the negative results seen for subject 2 were with blood specimens collected from two time points in 1997 and 1998 that tested weakly positive and negative for SRV antibodies, respectively. Although the tissue tropism of SRV in macaques is extensive and includes lymphoid and nonlymphoid cells (15, 23), the in vivo cellular tropism and intracellular localization of SRV in humans are not known. Thus, DNA lysates prepared from enriched PBL subpopulations from subject 1 and nuclear lysates prepared from the whole blood of both subjects were tested for SRV sequences by PCR analysis. SRV pol and gag sequences were not detected in either the nuclear lysates of both subjects or in monocyte, B-cell, CD4 T-cell, or CD8 T-cell subsets from subject 1 (Fig. 1B and C). PBL quantities were not sufficient to select T-cell subsets from subject 2 for PCR analysis. In addition, since both subjects were found to have SRV-2- specific neutralizing activity, their PBLs were also screened for SRV-2 gag-specific sequences. All samples from both subjects were negative for SRV-2 sequences using these gag primers (Fig. 1D). Animal inoculation. The single juvenile rhesus macaque inoculated intravenously with 10 ml of heparinized blood from subject 1 remains healthy and seronegative 21 months postinoculation. All attempts at virus isolation by cocultivation of monkey PBLs and peripheral lymph node cells with permissive cell lines and PCR analysis of monkey PBL and peripheral lymph node cells for SRV proviral DNA were negative. DISCUSSION The results of this study provide evidence that occupational exposure to NHPs may result in an increased risk of infection with SRV. To our knowledge, this is the first report of human sera demonstrating seroreactivity against SRV gag, pol, and env gene products. We demonstrate persistent seropositivity in one animal handler spanning 3 years and evidence of seroreversion in a second person occurring over a 2-year period. The persistent seropositivity observed in case 1 suggests continuous exposure to SRV antigens. However, the inability to isolate SRV from PBL cultures or detect evidence of SRV-infected cells in the circulation of either person despite the use of highly sensitive PCR methods suggests very low-level viremias. Collectively, these data suggest the presence of a persistent infection in subject 1 and a possible transient infection in subject 2. The findings seen in subject 1 are consistent with data obtained from macaques that are naturally infected with SRV (18, 20, 29). SRV infection in macaques is thought to result in persistent infection, although SRV may become latent in the face of a vigorous immune response (18). In macaque populations where SRV is enzootic, it has been observed that the PBLs of some animals with strong antibody responses by immunoblotting show no evidence of viral presence by either cocultivation or PCR (20). It has been suggested that PBLs may not be the optimal tissue to analyze for detection of latent SRV infections. In one study, SRV proviral DNA was detected in bone marrow and other tissues from infected, seropositive macaques, although their PBLs repeatedly tested negative (24). Unfortunately, such specimens were not available from the seropositive persons in the present study. The mechanisms determining activation and latency of SRV infection are not well understood. It is interesting that the only human case of active SRV infection thus far reported occurred in a patient with severe immunosuppression from human immunodeficiency virus infection/aids and lymphoma (2). The observed seroreversion in subject 2 is similar to that previously observed in a person who sustained a needle stick exposure to SIV (12). These data suggest that cross-species transmission of simian retroviruses may not always result in the establishment of a lifelong persistent infection. Although there is significant antigenic cross-reactivity among the five recognized SRV serotypes, based on neutralization data, both seropositive humans in our study showed evidence TABLE 2. Neutralization of SRV by immunoblot-positive sera from persons occupationally exposed to NHPs Serum sample (sample date a ) SRV type b Neutralization titer Subject 1 (7/31/98) 1 1:20 2 1:160 Subject 2 (1/30/97) 1 1:10 2 1:40 Negative human control 1 1:10 2 1:10 Negative macaque control 1 1:10 2 1:10 SRV-1-positive control 1 1: :10 SRV-2-positive control 1 1:10 2 1:320 a Dates are in the form month/day/year. b SRV-1 and SRV-2 were tested at 40 and 80 TCID 50 /well, respectively.

6 1788 LERCHE ET AL. J. VIROL. of exposure to SRV-2. The presence of neutralizing antibody against SRV-2, but not SRV-1, provides evidence of a virusspecific immune response rather than nonspecific neutralization, as both the SRV-1 and SRV-2 viruses used in the neutralization assay were produced in the same cell line (SupT1). These data are also consistent with the high prevalence of SRV-2 among captive macaque species, particularly pig-tailed (Macaca nemestrina) and cynomolgus (Macaca fascicularis) macaques. Contact with at least one of these two macaque species was reported by both subject 1 and subject 2. The risk for developing disease in SRV-infected humans or for secondary transmission to other humans is unknown. Spouses of both persons were unavailable for testing to determine whether this SRV seroreactivity is transmissible to humans, and while the absence of disease in both subjects is reassuring, our information is limited by the small sample size, the relatively short length of follow-up, and the absence of clinical observations coincident with infection and seroconversion. However, the anti-srv neutralizing-antibody titers seen in both seropositive persons may offer them some degree of immunologic protection from viremia and subsequent disease manifestation, as has been recently observed in SRV-2-infected macaques with similar antibody titers and low or undetectable viral loads (29). Subject 1 has shown persistent antibody to SRV over the 3-year period for which archived or follow-up serum samples were available, and it is possible that the duration of seropositivity may actually be much longer. Subject 1 has previously been found to be persistently infected with SFV (10). There is no antigenic cross-reactivity between SRV and SFV, and three other humans described as being persistently infected with SFV all tested SRV negative (10). To our knowledge, the finding of evidence of infection with two different simian retroviruses in a single individual is unprecedented. In contrast to STLV and SIV, both SRV and SFV are readily isolated from saliva and oropharyngeal secretions of infected NHPs (11, 16, 31), and penetrating bite wounds would represent a potentially efficient route of transmission for both agents. Transmission of SRV and SFV from a single exposure is unlikely, as the SFV infection in this person was derived from an AGM (Chlorocebus aethiops), a species not known to be a host for SRV. However, dual infection with two different simian retroviruses does serve to underscore the potential for cumulative exposure to multiple agents over a long career involving the handling of NHPs. The findings of this study add to the body of existing data regarding the potential risk of cross-species transmission of simian retroviruses to humans in persons occupationally exposed to NHPs and their tissues or body fluids. These findings reemphasize the importance of occupational safety practices, including the use of personal protective equipment to reduce the risk of exposure to these viruses, and of efforts to establish and maintain retrovirus-specific pathogen-free colonies of macaques. The precautions taken against herpesvirus B (cercopithecine herpesvirus 1) transmission from macaques to humans may also limit the transmission of SRV and other retroviruses (30). However, our findings also serve to reinforce the need for continued and expanded surveillance for crossspecies transmission among occupationally at-risk workers. ACKNOWLEDGMENTS We are grateful to Robin Weiss, Myra McClure, and Vladimir Liska for confirmatory PCR analysis of some samples from the study. REFERENCES 1. Allan, J. A Xenotransplantation at a crossroads: prevention versus progress. Nat. Med. 2: Bohannon, R. C., L. A. Donehower, and R. J. Ford Isolation of a type D retrovirus from B-cell lymphomas of a patient with AIDS. J. Virol. 65: Callahan, M. E., W. M. Switzer, A. L. Mathews, B. D. Roberts, W. Heneine, T. M. Folks, and P. A. Sandstrom Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact ORF-2 accessory gene. J. Virol. 73: Charman, J. P., R. Rahman, M. H. White, N. Kim, and R. V. Gilden Radio-immunoassay for major structural protein of Mason-Pfizer monkey virus: attempts to detect the presence of antigen or antibody in humans. Int. J. Cancer 19: Ford, R. J., L. A. Donehower, and R. C. Bohannon Studies on a type D retrovirus isolated from an AIDS patient lymphoma. AIDS Res. Hum. Retrovir. 8: Hahn, B. H., G. M. Shaw, K. M. De Cock, and P. M. Sharp AIDS as a zoonosis: scientific and public health implications. Science 287: Heneine, W., R. F. Khabbaz, R. B. Lal, and J. E. Kaplan Sensitive and specific polymerase chain reaction assays for diagnosis of human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infections in HTLV-1/IIseropositive individuals. J. Clin. Microbiol. 30: Heneine, W., N. W. Lerche, T. Woods, T. Spira, J. M. Liff, W. Eley, J. L. Yee, J. L. Kaplan, and R. F. Khabbaz The search for human infection with simian type D retroviruses. J. Acquir. Immune Defic. Syndr. 6: Heneine, W., S. Yamamoto, W. M. Switzer, T. Spira, and T. M. Folks Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 171: Heneine, W., W. M. Switzer, P. Sandstrom, J. Brown, S. Vedapuri, C. A. Schable, A. S. Khan, N. W. Lerche, M. Schweizer, D. Neumann-Haeflin, L. E. Chapman, and T. M. Folks Identification of a human population infected with simian foamy viruses. Nat. Med. 4: Johnston, P. B A second immunologic type of simian foamy virus: monkey throat infections and unmasking of both types. J. Infect. Dis. 109: Khabbaz, R. F., W. Heneine, J. R. George, B. Parekh, T. Rowe, T. Woods, W. M. Switzer, H. M. McClure, M. Murphey-Corb, and T. M. Folks Brief report: infection of a laboratory worker with simian immunodeficiency virus. N. Engl. J. Med. 330: Krause, H., V. Wunderlich, and W. Uckert Molecular cloning of a type D retrovirus from human cells (PMFV) and its homology to simian acquired immunodeficiency type D retroviruses. Virology 173: Kzhyshkowska, J. G., A. V. Kiselev, G. A. Gordina, V. I. Kurmashow, N. M. Portjanko, A. S. Ostashkin, and K. V. Ilyin Markers of type D retroviruses in children with Burkitt s-type lymphoma. Immunol. Lett. 53: Lackner, A. A., M. H. Rodriguez, C. E. Bush, R. J. Munn, H. S. Kwang, P. F. Moore, K. G. Osborn, P. A. Marx, M. B. Gardner, and L. J. Lowenstine Distribution of a macaque immunosuppressive type D retrovirus in neural, lymphoid, and salivary tissues. J. Virol. 62: Lerche, N. W., K. G. Osborn, P. A. Marx, S. Prahalada, D. H. Maul, L. J. Lowenstine, R. J. Munn, M. L. Bryant, R. V. Henrickson, L. O. Arthur, R. V. Gilden, C. S. Barker, E. Hunter, and M. B. Gardner Inapparent carriers of simian acquired immune deficiency syndrome type D retrovirus and disease transmission with saliva. J. Natl. Cancer Inst. 77: Lerche, N. W., J. L. Yee, and M. B. Jennings Establishing specific retrovirus-free breeding colonies of macaques: an approach to primary screening and surveillance. Lab. Anim. Sci. 44: Lerche, N. W Epidemiology and control of simian type D retrovirus infection in captive macaques, p In S. Matano, R. H. Tuttle, H. Ishida, and M. Goodman (ed.), Topics in primatology, vol. 3. University of Tokyo Press, Tokyo, Japan. 19. Lerche, N. W., W. Heneine, J. E. Kaplan, T. Spira, J. L. Yee, and R. F. Khabbaz An expanded search for human infection with simian type D retrovirus. AIDS Res. Hum. Retrovir. 11: Lerche, N. W., R. F. Cotterman, M. D. Dobson, J. L. Yee, A. N. Rosenthal, and W. M. Heneine Screening for simian type D retrovirus infection in macaques using nested polymerase chain reaction. Lab. Anim. Sci. 47: Lowenstine, L. J., and N. W. Lerche Retrovirus infections of nonhuman primates: a review. J. Zoo Anim. Med. 19: Marx, P. A., M. L. Bryant, K. G. Osborn, D. H. Maul, N. W. Lerche, L. J. Lowenstine, J. D. Kluge, C. P. Zaiss, R. V. Henrickson, S. M. Shiigi, B. S. Wilson, A. Malley, L. Olson, W. P. McNulty, L. O. Arthur, R. V. Gilden, C. S. Barker, E. Hunter, R. J. Munn, G. Heidecker-Fanning, and M. B. Gardner

7 VOL. 75, 2001 HUMAN SRV INFECTION Isolation of a new serotype of simian acquired immune deficiency syndrome type D retrovirus from Celebes black macaques (Macaca nigra) with immune deficiency and retroperitoneal fibromatosis. J. Virol. 56: Maul, D. H., C. P. Zaiss, M. R. MacKenzie, S. M. Shiigi, P. A. Marx, and M. B. Gardner Simian retrovirus D serogroup 1 has a broad cellular tropism for lymphoid and nonlymphoid cells. J. Virol. 62: Moazed, T. C., and M. E. Thouless Viral persistence of simian type D retrovirus (SRV-2/W) in naturally infected pig-tailed macaques (Macaca nemestrina). J. Med. Primatol. 22: Morozov, V. A., P. O. Ilyinskii, W. A. Uckert, W. Wunderlich, and K. V. Ilyin Antibodies to structural and nonstructural gag-coded proteins of type D retroviruses in humans with lymphadenopathy and AIDS. Int. J. Tissue React. 11: Morozov, V. A., F. Saal, A. Gessain, A. Terrinha, and J. Peries Antibodies to gag gene-coded polypeptides of Mason-Pfizer monkey virus in healthy people from Guinea Bissau. Intervirology 32: Morozov, V. A., S. Lagaye, L. Lyakh, and J. ter Muelen Type D retrovirus markers in healthy Africans from Guinea. Res. Virol. 147: Popovic, M., V. S. Kalyanaraman, M. S. Reitz, and M. G. Sarngadharan Identification of the RPMI 8226 retrovirus and its dissemination as a significant contaminant of some widely used human and marmoset cell lines. Int. J. Cancer 30: Rosenblum, L. L., R. A. Weiss, and M. O. McClure Virus load and sequence variation in simian retrovirus type 2 infection. J. Virol. 74: Sotir, M., W. M. Switzer, C. Schable, J. Schmitt, C. Vitek, and R. F. Khabbaz Risk of occupational exposure to potentially infectious nonhuman primate materials and to simian immunodeficiency virus. J. Med. Primatol. 26: Swack, N., A. Schoentag, and G. Hsiung Foamy virus infection of rhesus and green monkeys in captivity. Am. J. Epidemiol. 92: Switzer, W. M., D. Pieniazek, P. Swanson, H. H. Samdal, V. Soriano, R. F. Khabbaz, J. E. Kaplan, R. B. Lal, and W. Heneine Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes. J. Virol. 69: Weiss, R Retroviral zoonoses. Nat. Med. 4: Downloaded from on December 16, 2018 by guest